NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=143342&from=4 CLASS PERIOD: March 13, 2023 to March 11, 2 ...

Core Viewpoint - Zynex, Inc. is facing significant financial, regulatory, and legal challenges, including a class action lawsuit and a downgrade in stock outlook by RBC Capital Markets, which has reduced its price target to $5 per share from an initial $11, reflecting a 55% decrease in valuation outlook [1][2][3]. Financial Performance - The company reported a disappointing fourth-quarter 2024 earnings report with a year-over-year revenue decline of approximately 2%, totaling $46.0 million, and a net loss of $0.02 per share compared to a profit of $0.04 per share in the same period the previous year [3][5]. - RBC Capital Markets has downgraded Zynex's rating to "Sector Perform" from "Outperform," citing a lack of clarity regarding the company's operational and commercial prospects following the recent financial disclosures [4]. Legal and Regulatory Issues - Zynex is facing a securities class action lawsuit alleging that the company engaged in an "oversupplying" scheme, which purportedly inflated revenue figures and drew scrutiny from insurers, including Tricare [7][8]. - The lawsuit claims that Zynex failed to disclose the potential adverse consequences of its practices, which could lead to network exclusions and government penalties [7]. - The temporary suspension of payments from Tricare, Zynex's largest customer, is a significant factor affecting the company's financial stability, as the insurer reviews past claims [5][6]. Investor Sentiment - The recent developments, including the lowered outlook and specifics of the class action, have raised serious concerns among investors regarding Zynex's disclosures and overall accountability [11].

Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for alleged misconduct during the class period from March 13, 2023, to March 11, 2025, following reports of oversupplying medical devices and a significant revenue shortfall due to payment delays from insurers [1][4]. Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2]. Legal Developments - A class action lawsuit has been initiated on behalf of investors who purchased Zynex securities during the specified class period, with a deadline of May 19, 2025, for potential lead plaintiff applications [1][2]. - The lawsuit follows a report by medical journal STAT, which accused Zynex of an "oversupplying scheme" that led to insurers removing the company from their networks [3]. Financial Performance - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 and the full year of 2024, attributing it to slower payments from certain payers, including a temporary suspension of payments from Tricare [4]. - Following the financial report, Zynex's stock price plummeted by $3.59 per share, or 51%, closing at $3.41 per share on March 12, 2025 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 19, 2025 [2][4]. Group 1: Allegations Against Zynex - The complaint alleges that Zynex and its executives made false or misleading statements and failed to disclose critical information, including shipping excess products, inflating revenue, and facing scrutiny from insurers like Tricare [4]. - A report published by medical journal STAT accused Zynex of an "oversupplying scheme," leading to insurers removing the company from their networks [5]. - Following the report, Zynex's stock price dropped by $0.50 per share, or 5%, to close at $9.35 on June 4, 2024, amid heavy trading volume [5]. Group 2: Financial Performance and Market Reaction - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers and a temporary suspension of payments from Tricare [6]. - The announcement led to a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51.3%, closing at $3.41 on March 12, 2025, also on unusually heavy trading volume [7].

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. alleging securities fraud that affected investors between March 13, 2023, and March 11, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2]. - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including the U.S. military health insurance program, Tricare [2]. - The complaint suggests that Zynex may face adverse consequences such as removal from insurer networks and federal penalties due to these practices [2]. - Defendants' positive statements regarding Zynex's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Zynex, Inc. during the specified timeframe have until May 19, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, April 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP ...

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Zynex securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of ...

Core Viewpoint - Zynex, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements and inflating revenue through improper shipping practices during the class period from March 13, 2023, to March 11, 2025 [2]. Group 1: Allegations and Legal Context - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [2]. - As a result of these practices, Zynex is likely to face adverse consequences, including potential removal from insurer networks and penalties from the federal government [2]. - The positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares of Zynex during the specified class period are encouraged to register for the class action lawsuit by May 19, 2025 [3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [3]. - There is no cost or obligation for shareholders to participate in this case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses from misleading statements or omissions that led to artificial inflation of stock prices [4].

PHILADELPHIA, April 9, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired ZYNEX securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of the c ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-for ...